Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
To compare the effect of high-dose valacyclovir (1 gram orally twice daily) versus
standard-dose acyclovir (400 mg orally twice daily) on the frequency of genital HSV
reactivation and on plasma HIV-1 levels among HSV-2/HIV-1 co-infected individuals. The
investigators hypothesize that high-dose valacyclovir will result in greater reduction in
plasma HIV-1 and genital HSV reactivation.